Physician profile
James Ho
NPI 1891701223
$8,323.87
in general payments reported to CMS, 2019-2025
29 companies · $878 in 2025
The $878 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,555 · 2020: $1,226 · 2021: $2,202 · 2022: $1,178 · 2023: $822 · 2024: $463 · 2025: $878.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,149 · Education: $14.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,148.99 |
| Education | $14.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,823.46 | 2019-2023 | Symtuza |
| Gilead Sciences, INC. | $1,608.83 | 2019-2025 | Biktarvy |
| Viiv Healthcare Company | $1,138.46 | 2019-2025 | Dovato, Apretude, Rukobia |
| Abbvie INC. | $903.38 | 2019-2025 | |
| Janssen Products, LP | $575.91 | 2019-2022 | |
| Alkermes, INC. | $359.30 | 2019-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $304.74 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $296.73 | 2019-2024 | Ingrezza |
| Indivior INC. | $199.40 | 2019-2025 | Sublocade |
| Merck Sharp & Dohme LLC | $199.02 | 2019-2025 | Gardasil 9, Capvaxive |
| Dynavax Technologies Corporation | $124.28 | 2021-2022 | |
| Theratechnologies INC. | $119.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $82.40 | 2025 | Cobenfy |
| Mylan Specialty L.P. | $81.77 | 2020-2021 | |
| Lilly USA, LLC | $81.06 | 2025 | Zepbound, Mounjaro |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $76.93 | 2023 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Ascensia Diabetes Care US INC. | $67.60 | 2019-2020 | |
| Lundbeck LLC | $44.41 | 2022-2025 | Abilify Maintena |
| Janssen Pharmaceuticals, INC | $32.82 | 2022-2025 | Invega Sustenna |
| Mannkind Corporation | $24.60 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.08 | 2024 | |
| Glaxosmithkline, LLC. | $22.67 | 2021 | |
| Exact Sciences Corporation | $22.62 | 2023 | Cologuard Collection Kit |
| Emd Serono, INC. | $22.61 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.94 | 2023 | Xifaxan |
| Napo Pharmaceuticals INC | $18.82 | 2019 | |
| Sunovion Pharmaceuticals INC. | $18.17 | 2019 | |
| Shield Therapeutics INC | $16.07 | 2025 | |
| Orexo US, INC. | $13.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.